1 citations,
January 1995 in “Journal of Investigative Dermatology” RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.
49 citations,
January 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” RU 58841 may treat acne, hair loss, and excessive hair growth.
62 citations,
May 1997 in “Journal of Pharmaceutical Sciences” Sebaceous glands in the skin play a key role in absorbing the antiandrogen drug RU 58841, especially when it's encapsulated in liposomes.
20 citations,
December 1995 in “International Journal of Pharmaceutics” Liposomes can make the antiandrogen RU 58841 more effective for skin application by reducing absorption, increasing skin retention, and targeting sebaceous structures.
16 citations,
October 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
10 citations,
November 1997 in “British Journal of Dermatology” RU58841 significantly increases hair growth rate and initiates more hair cycles, but doesn't affect hair thickness, suggesting it could be a new treatment for baldness.
33 citations,
January 1997 in “Endocrinology” Testosterone can slow down hair growth when combined with certain cells from bald scalps, and this effect can be blocked by an androgen receptor blocker.
4 citations,
January 2014 in “RSC Advances” A new, less toxic and more efficient method to create the anti-baldness compound RU58841 was developed in 2014.
88 citations,
February 2008 in “Journal of Medicinal Chemistry” Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.
18 citations,
January 1998 in “Endocrine” RU58841, a nonsteroidal anti-androgen, showed potential as a topical treatment for hair loss, increasing hair density, thickness, and length without systemic side effects in Stumptailed Macaques.
58 citations,
June 2000 in “The Journal of Steroid Biochemistry and Molecular Biology” Different types of androgens bind differently to two receptors, AR1 and AR2, in Atlantic croaker's brain and ovarian tissues, suggesting these receptors may control different androgen actions in fish.
17 citations,
January 2015 in “MedChemComm” New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
20 citations,
February 2002 in “Expert Opinion on Therapeutic Patents” New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.
December 2011 in “Drug Research” The document shows the state of pharmaceutical patents as of 1999, focusing on treatments for various diseases.
19 citations,
January 1997 in “Endocrinology” Testosterone can slow hair growth in adult monkeys, but a blocker called RU 58841 can counteract this and potentially help hair regrow.
19 citations,
January 1997 in “Dermatologic Clinics” Most treatments for hair loss in 1997 were not effective for most people, and maintaining hair growth was difficult.
12 citations,
April 1995 in “Journal of Medicinal Chemistry” The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.
3 citations,
February 2005 in “Expert Opinion on Investigational Drugs” New treatments for hair loss are being developed using molecular biology.
11 citations,
August 1997 in “Expert Opinion on Therapeutic Patents” Many potential alopecia treatments need more testing to confirm they promote acceptable hair growth with minimal side effects.
60 citations,
January 2014 in “Anais Brasileiros De Dermatologia” Nanotechnology in dermatology shows promise for better drug delivery and treatment effectiveness but requires more safety research.
49 citations,
April 2015 in “Emerging Infectious Diseases” Artesunate is generally safe for severe malaria, but patients should be monitored for delayed anemia after treatment.
5 citations,
February 2015 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” OCT can non-invasively diagnose follicular keratosis and other hair follicle disorders.
5 citations,
June 2012 in “The journal of investigative dermatology/Journal of investigative dermatology” Putting thymidine dinucleotide on newborn mice's skin can delay and reduce skin cancer.
1 citations,
November 2008 in “Acta crystallographica” Scientists successfully created and analyzed the structure of a part of the human androgen receptor with specific modulators and a peptide to understand how it binds differently in various tissues.
February 1998 in “American Journal of Health-System Pharmacy” Yale-New Haven Hospital won a top award for greatly improving asthma care and reducing related hospital visits and costs.
Men with depression and marijuana usage are more likely to be treated for lower urinary tract symptoms/benign prostatic hyperplasia.
124 citations,
June 2020 in “Cell Stem Cell” Fat cells in the skin help start healing and form important repair cells after injury.
12 citations,
June 2019 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” Proper skin toxicity management in chemotherapy is key to continuing treatment and keeping patient quality of life high.
14 citations,
February 2023 in “Frontiers in immunology” Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.
March 1998 in “Journal of Dermatological Science” Combining RU58841 and minoxidil significantly increases hair growth.